- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05130359
Evaluation of the Sleep-relieving Effect of Banana Peel Extract
July 28, 2025 updated by: TCI Co., Ltd.
Explore Whether Banana Peel Extract Can Improve Sleep
Banana peel has the potential to improve sleep quality.
The purpose of this research is to test the effect of banana peel on improving sleep quality.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Insomnia is one of the most frequently complained sleep problems in sleep disorders, and in recent years has been regarded by the medical community as a disease that seriously affects people's lives and quality of life.
The problem of perishable and perishable causes a great burden on the environment.
However, banana peels actually contain many functional ingredients, such as dietary fiber, minerals, alkaloids, flavonoids, phenols, saponins, tannins and dopamine, etc. Banana peel contains more total phenols and total flavonoids than banana pulp.
Studies have pointed out that banana peel extraction can inhibit the growth of fungi and bacteria.
In addition, it also has antioxidant, anti-depressant, and diuretic functions.
Banana peel can also improve the performance of tryptophan metabolism-related genes
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan
- Taipei Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
1.20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent.
2.Pittsburgh Sleep Quality Index (PSQI) score> 5
Exclusion Criteria:
- Taking sleeping pills and melatonin
- People suffering from mental illness
- Pregnant or breastfeeding women
- People who are known to be allergic to bananas
- Have heart-related diseases
- People with symptoms of sleep cessation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
|
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
|
|
Experimental: Banana peel extract
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
|
take 2 tablets 2 hours before bedtime for 4 consecutive weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep monitoring
Time Frame: at 4 week after taking test sample
|
Detect the electrical activity of the heart in the potential difference between two specific points on the body surface to reflect the state of sleep
|
at 4 week after taking test sample
|
|
Serotonin
Time Frame: at 4 week after taking test sample
|
Venous blood was sampled to measure concentrations of Serotonin
|
at 4 week after taking test sample
|
|
Melatonin
Time Frame: at 4 week after taking test sample
|
Collect saliva samples in the morning upon waking to measure melatonin concentration.
|
at 4 week after taking test sample
|
|
Sleeping quality
Time Frame: at 4 week after taking test sample
|
The Pittsburgh Sleep Quality Index (PSQI) will be utilized to assess sleeping quality.
The minimum value is 0, the maximum value is 42.
The higher the score, the worse the outcome.
|
at 4 week after taking test sample
|
|
Insomnia Severity
Time Frame: at 4 week after taking test sample
|
The Insomnia Severity Index (ISI) will be utilized to assess insomnia severity.
The minimum value is 0, the maximum value is 28.
The higher the score, the worse the outcome.
|
at 4 week after taking test sample
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of liver function biomarkers (AST, ALT) of blood
Time Frame: at 4 week after taking test sample
|
Fasting venous blood was sampled to measure liver function biomarkers
|
at 4 week after taking test sample
|
|
The change of renal function biomarkers (creatinine, BUN) of blood
Time Frame: at 4 week after taking test sample
|
Fasting venous blood was sampled to measure renal function biomarkers
|
at 4 week after taking test sample
|
|
The change of fasting blood glucose
Time Frame: at 4 week after taking test sample
|
Fasting venous blood was sampled to measure concentrations of blood glucose
|
at 4 week after taking test sample
|
|
The change of Blood lipids profiles (Total-Cholesterol, HDL-C, LDL-C, triglycerides)
Time Frame: at 4 week after taking test sample
|
Fasting venous blood was sampled to measure concentrations of Blood lipids profiles (Total-Cholesterol, HDL-C, LDL-C, triglycerides)
|
at 4 week after taking test sample
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hsin-Chien Lee, Doctor, Taipei Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2022
Primary Completion (Actual)
May 31, 2024
Study Completion (Actual)
May 31, 2025
Study Registration Dates
First Submitted
October 21, 2021
First Submitted That Met QC Criteria
November 11, 2021
First Posted (Actual)
November 23, 2021
Study Record Updates
Last Update Posted (Actual)
July 30, 2025
Last Update Submitted That Met QC Criteria
July 28, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- N202103033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Attention
-
Barcelona Institute for Global HealthRecercaixa; Centre de Recerca per a l'Educació Científica i Matemàtica (CRECIM) and other collaboratorsCompletedRisk Behavior | Attention Impaired | Risk-Taking | Social Preferences | Decision Making | AttentionSpain
-
University of HaifaCompletedCognitive Change | Attention Impaired | Mental Health IssueIsrael
-
Kutahya Health Sciences UniversityNot yet recruitingMild Cognitive Impairment | Attention Impaired | Adolescent Development
-
Julie FaietaCompleted
-
University of HaifaRecruitingAttention Impaired | Mental Health Issue | RuminationIsrael
-
University of ZurichUniversity of LuebeckRecruitingExploiting the Potential of Neural Attentional Control to Overcome Hearing Impairment (NeurAttContr)Hearing Loss | Tinnitus | Attention ImpairedSwitzerland
-
Kessler FoundationNational Institute on Disability, Independent Living, and Rehabilitation...RecruitingTraumatic Brain Injury | Attention Impaired | Emotional RegulationUnited States
-
VA Office of Research and DevelopmentRecruiting
-
University of LiegeCompleted
-
European Georges Pompidou HospitalCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States